Retro Biosciences inks blood disorder deal as Sam Altman-backed biotech seeks $1B in fundsnews2025-05-20T04:01:33+00:00May 20th, 2025|Endpoints News|
CellCentric raises $120M to treat multiple myeloma with capsulenews2025-05-19T11:30:18+00:00May 19th, 2025|Endpoints News|
Apnimed posts first set of Phase 3 sleep apnea results, aims for approval filing in 2026news2025-05-19T10:00:51+00:00May 19th, 2025|Endpoints News|
It’s been three months without a biotech IPOnews2025-05-16T11:00:26+00:00May 16th, 2025|Endpoints News|
Eli Lilly teams up with RNA editing biotech for hearing lossnews2025-05-15T17:30:49+00:00May 15th, 2025|Endpoints News|
Pathos AI collects $365M to fuel data-driven oncology studiesnews2025-05-15T14:44:09+00:00May 15th, 2025|Endpoints News|
AbbVie doubles down on siRNA with $335M upfront bet on ADARxnews2025-05-14T13:00:05+00:00May 14th, 2025|Endpoints News|
Dutch biotech Azafaros gets $146M for Phase 3 trials in three metabolic disordersnews2025-05-13T05:00:54+00:00May 13th, 2025|Endpoints News|
Exclusive: Patrick Hsu’s startup Stylus Medicine launches, looks beyond CRISPR for gene insertion technews2025-05-12T15:27:02+00:00May 12th, 2025|Endpoints News|
Chronic care startup Omada Health files to go publicnews2025-05-09T22:17:13+00:00May 9th, 2025|Endpoints News|
